Patent describes use of quantum resonance interferometry technology for detection and quantitation of biomolecular events above and below background noise
ViaLogy, inventor and developer of active signal processing software, reports that it has been issued US patent 6,671,625, which describes use of its quantum resonance interferometry (QRI) technology for detection and quantitation of biomolecular events above and below background noise.
The patent extends QRI to protein arrays and broadens applications of QRI to proteomics, pathway optimisation, high-throughput screening, cellular assays and time-based dosing studies by gene expression.
ViaLogy already has been issued three US patents, numbers 6,245,511, 6,142,681 and 6,136,541, which describe the application of QRI technology to the analysis and interpretation of hybridised biochip and DNA microarray patterns including diagnostic applications.
"As demonstrated by our recently announced study with Zeptosens, our customers can now work with confidence at levels of sensitivity, specificity and reproducibility far below background noise and unattainable by other commercially available technology." said Doug Lane, ViaLogy's president and CEO.
"This patent further strengthens ViaLogy's intellectual property position, especially for proteins, time-based measurements, and the discovery and monitoring of biomarkers".
Now available, ViaLogy microarray analysis service (Vmaxs), is a highly focused application service for gene expression data, based on ViaLogy's QRI technology.
Designed for large-scale users of microarrays such as major pharmaceutical, biotech and agricultural companies and institutional core laboratories, Vmaxs reprocesses microarray raw data files from existing microarray instrumentation and databases and is available on a pay-per-use basis.
The company expects Vmaxs to be available on-line and user-driven later this month (January 2004) for several microarray formats and will expand to other formats.
